THUNDER BAY, Ontario, April 30, 2012 /PRNewswire/ -- IGY Immune Technology & Life Sciences has acquired manufacturing capabilities to produce its proprietary IgY products. IgY from chicken egg yolks has long been recognized among scientists for its immune enhancing benefits in humans as well as its ability to deliver customized antibodies to fight sickness and maintain good health. Until now, a consistent, purified source has not been available commercially. IGY Immune Technology & Life Sciences expects to be producing IgY by the end of 2012.
"The acquisition of this facility and our existing intellectual property position make IGY Immune Technology the world's leader in the production of IgY," said Terry Dyck, chief executive officer. "The production of IgY at higher purity levels and lower cost will create a number of product development opportunities across the nutrition, cosmetic, pharmaceutical and animal health industries."
The existing world supply of IgY is very limited and expensive. IGY Immune Technology's unique process is able to produce commercial quantities of IgY from chicken egg yolk. The manufacturing facility is in close proximity to major egg producers and the production process utilizes no toxic chemicals allowing the egg yolk to be returned back into the food supply.
IGY Immune Technology & Life Sciences is already in the commercialization process with its first product and has a number of business partnerships in development with major life sciences corporations. An opportunity for investment in IGY Immune Technology is also available.
"We're establishing ourselves already with leading companies that have been following IgY developments," said Dyck. "We're moving forward in securing these partnerships as well as providing a profitable opportunity for investors."
For more information about IGY Immune Technology & Life Sciences, visit its web site at: http://www.igylifesciences.com
SOURCE IGY Immune Technology & Life Sciences